🇺🇸 VCEL — Vericel Corporation

Nombre completo

Vericel Corporation

Divisa

USD

Mercado

NasdaqGM

Sector

Salud

Industria

Biotechnology

Empleados

398

PER ⓘ

87,43 (puede no estar actualizado)

Dividend yield

0,00% (puede no estar actualizado)

Precio objetivo analistas

59,71 USD (puede no estar actualizado)

Primera cotización

04/02/1997

Precio actualizado

hace 18 horas

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.